RESULTS

1. PREOPERATIVE PLASMA CONCENTRATION OF MMP-9/TIMP-1 COMPLEXES IS NOT ASSOCIATED WITH DISEASE OUTCOME IN PRIMARY BREAST CANCER (N=483)Anne-Sofie Schrohl1, SidseØrnbjerg Würtz1, Susanne Møller2, Birgitte Sander Nielsen1, Henning T. Mouridsen2, and Nils Brünner11 University of Copenhagen, Faculty of Life Sciences & Sino-Danish Breast Cancer Research Centre, Copenhagen, Denmark2 Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, DenmarkContact: sofie@life.ku.dk AIM & HYPOTHESIS RESULTS Both Matrix Metalloproteinase-9 (MMP-9) and Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) are associated with a poor prognosis in breast cancer. Here, our aim was to measure the concentration of MMP-9/TIMP-1 complexes in plasma from primary breast cancer patients and to evaluate whether these levels are associated with disease outcome. The hypothesis was that high plasma levels of MMP-9/TIMP-1 complexes are associated with increased recurrence risk in primary breast cancer patients. Table 1. Patient and tumor characteristics and association with MMP-9/TIMP-1 complexes Figure 1. Recurrence-free survival of patients grouped in quartiles by plasma MMP-9/TIMP-1 level Plasma MMP-9/TIMP-1 complex levels were not associated with age, lymph node status, steroid hormone receptor status, or tumor size. Significant associations with tumor grade (p=0.04) and menopausal status (p=0.001) were found. Plasma levels of MMP-9/TIMP-1 complexes were not associated with recurrence-free survival (logrank test p=0.9565). Proportion alivewithoutrecurrence ASSAY AND SAMPLES MMP-9/TIMP-1 COMPLEX ELISA The human MMP-9/TIMP-1 Complex DuoSet® ELISA Development System (R&D Systems, Inc.) was validated for measurement of MMP-9/TIMP-1 complex levels in human plasma. The validation process included investigation of reproducibility (intra-assay, inter-assay), recovery, and linearity upon dilution of samples. PLASMA SAMPLES Preoperative EDTA plasma samples from 483 consecutively enrolled primary breast cancer patients were analyzed. Prior to analysis, samples were diluted in reagent diluent as recommended by the manufacturer (1:3). The median MMP-9/TIMP-1 complex concentration was 2.06 ng/mL(range, 0.11 - >14.8 ng/mL). DATA ANALYSIS The possible associations between MMP-9/TIMP-1 plasma level and patient- and tumor characteristics were analyzed using a Χ2 test. The possible association with recurrence-free survival was investigated using a logrank test and a multivariable Cox proportional hazards model. In the analyses, patients were grouped in quartiles based on their plasma MMP-9/TIMP-1 complex level. Recurrence-free survival was defined as survival without breast cancer relapse, contralateral breast cancer, other malignant disease and death without a previous relapse. CONCLUSIONS • No association was found between plasma concentration of MMP-9/TIMP-1 complexes and disease outcome • These results suggest that other fractions of MMP-9 and TIMP-1 carry prognostic information, e.g. free MMP-9 and TIMP-1 or MMP-9 and TIMP-1 bound to other plasma proteins Table 2. Multivariable Cox proportional hazards model of recurrence-free survival Only age ≥ 70 years and steroid hormone receptor status contributed significantly to the multivariable model. MMP-9/TIMP-1 complex levels were not associated with recurrence-free survival. ACKNOWLEDGEMENTS This work was supported by The Danish Cancer Society Anne-SofieSchrohl is supported by the Danish Council for Independent Research | Medical Sciences REFERENCES Li H. et al (2004). “Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma.” Breast Cancer Res Treat 88: 75-85 Somiari S.B. et al (2006). “Circulating MMP2 and MMP9 in breast cancer – Potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories.” Int J Cancer 119: 1403-1411 Würtz S.Ø. et al (2008). “Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study.” Mol Cell Proteomics 7(2): 424-430